Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
REHOVOT, Israel and BRIDGEWATER, N.J., July 26, 2017 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the three and six months ended June 30, 2017, and will host a corporate update conference call and webcast at 8:30am Eastern Time on Wednesday, August 9, 2017.
| Conference Call & Webcast | |
| Wednesday, August 9, 2017 @ 8:30 am Eastern Time | |
| Toll Free: | 877-780-3381 |
| International: | 913-312-1403 |
| Conference ID: | 2390109 |
| Webcast: | http://public.viavid.com/index.php?id=125169 |
| Replays, Available through August 23rd: | |
| Toll-Free: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 2390109 |
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
For more information, please visit www.foamixpharma.com.
Contact: Ilan Hadar, Country Manager & CFO Foamix Pharmaceuticals Ltd. +972-8-9316233 [email protected] US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 [email protected]
